

# LY3200882

**Catalog No: tcsc0023129**



## Available Sizes

---

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

---

**CAS No:**

1898283-02-7

**Formula:**

$C_{24}H_{29}N_5O_3$

**Pathway:**

TGF-beta/Smad

**Target:**

TGF- $\beta$  Receptor

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 130 mg/mL (298.49 mM; Need ultrasonic and warming)

**Observed Molecular Weight:**

435.52


## Product Description

LY3200882 is a novel and highly selective inhibitor of **TGF- $\beta$  receptor type 1 (TGF $\beta$ RI)**.

IC50 & Target: TGFβRI<sup>[1]</sup>

**In Vitro:** LY3200882 is a novel, highly selective inhibitor of TGF-β receptor type 1 (TGFβRI). LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation *in vitro* in tumor and immune cells. LY3200882 has shown anti-metastatic activity *in vitro* in migration assays. In *in vitro* immune suppression assays, LY3200882 has shown the ability to rescue TGFβ1 suppressed or T regulatory cell suppressed naïve T cell activity and restore proliferation<sup>[1]</sup>.

**In Vivo:** LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation *in vivo* in subcutaneous tumors in a dose dependent fashion. LY3200882 has shown anti-metastatic activity *in vivo* in an experimental metastasis tumor model (intravenous EMT6-LM2 model of triple negative breast cancer)<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!